人骨肉瘤的辅助干扰素治疗
Adjuvant interferon treatment in human osteosarcoma.
作者信息
Strander H, Bauer H C, Brosjö O, Kreicbergs A, Lindholm J, Nilsonne U, Silfverswärd C, Szamosi A
出版信息
Cancer Treat Res. 1993;62:29-32. doi: 10.1007/978-1-4615-3518-8_5.
An update of the adjuvant trial on osteosarcoma in Sweden comparing patients receiving natural interferon (IFN) alpha with a high-dose chemotherapy group and a nonadjuvant group is presented. The overall survival for the IFN group is 49%, for the chemotherapy group 54%, and for the nonadjuvant group 35%. Trial evaluation was complicated by group differences with respect to various clinicopathologic features of prognostic significance. The role of IFN in the treatment of osteosarcoma can still not be established.
本文介绍了瑞典骨肉瘤辅助试验的最新情况，该试验比较了接受天然α干扰素治疗的患者、高剂量化疗组患者和非辅助治疗组患者。干扰素组的总生存率为49%，化疗组为54%，非辅助治疗组为35%。由于各组在具有预后意义的各种临床病理特征方面存在差异，试验评估变得复杂。干扰素在骨肉瘤治疗中的作用仍未确定。
Zotero 插件